These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17456583)

  • 1. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.
    Schentag JJ; Hill G; Chu T; Rayner CR
    J Clin Pharmacol; 2007 Jun; 47(6):689-96. PubMed ID: 17456583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oseltamivir in young and very elderly subjects.
    Abe M; Smith J; Urae A; Barrett J; Kinoshita H; Rayner CR
    Ann Pharmacother; 2006 Oct; 40(10):1724-30. PubMed ID: 16940405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.
    Jhee SS; Yen M; Ereshefsky L; Leibowitz M; Schulte M; Kaeser B; Boak L; Patel A; Hoffmann G; Prinssen EP; Rayner CR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3687-93. PubMed ID: 18676886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
    Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D
    Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oseltamivir in breast milk and maternal plasma.
    Greer LG; Leff RD; Rogers VL; Roberts SW; McCracken GH; Wendel GD; Sheffield JS
    Am J Obstet Gynecol; 2011 Jun; 204(6):524.e1-4. PubMed ID: 21457910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.
    Washington C; Moreira S; Haznedar J; Goelzer P; Chen YC
    Drug Metab Pharmacokinet; 2014; 29(2):141-7. PubMed ID: 24025983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
    Jittamala P; Pukrittayakamee S; Tarning J; Lindegardh N; Hanpithakpong W; Taylor WR; Lawpoolsri S; Charunwattana P; Panapipat S; White NJ; Day NP
    Antimicrob Agents Chemother; 2014; 58(3):1615-21. PubMed ID: 24366750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
    Morimoto K; Kishimura K; Nagami T; Kodama N; Ogama Y; Yokoyama M; Toda S; Chiyoda T; Shimada R; Inano A; Kano T; Tamai I; Ogihara T
    J Pharm Sci; 2011 Sep; 100(9):3854-61. PubMed ID: 21607954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.
    Uchimura N; Kuwahara H; Kumagai Y; Mishima K; Inoue Y; Rayner CR; Toovey S; Davies BE; Hosaka Y; Abe M; Prinssen EP
    Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):309-14. PubMed ID: 21592308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
    Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
    Davies BE
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.
    Instiaty I; Lindegardh N; Jittmala P; Hanpithakpong W; Blessborn D; Pukrittayakamee S; White NJ; Tarning J
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2858-62. PubMed ID: 23507284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oseltamivir according to trimester of pregnancy.
    Greer LG; Leff RD; Rogers VL; Roberts SW; McCracken GH; Wendel GD; Sheffield JS
    Am J Obstet Gynecol; 2011 Jun; 204(6 Suppl 1):S89-93. PubMed ID: 21492824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.